Research programme: specific progesterone receptor modulators - Novus Therapeutics

Drug Profile

Research programme: specific progesterone receptor modulators - Novus Therapeutics

Alternative Names: CP 8661; CP 8668; CP 8816; CP 8863

Latest Information Update: 12 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Tokai Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Uterine diseases

Most Recent Events

  • 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
  • 09 Jun 2009 Programme licensed to Tokai Pharmaceuticals worldwide
  • 09 Jun 2009 Preclinical trials in Uterine disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top